相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities
Ariel E. Marciscano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death
Chang W. Song et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial
Douglas H. Brand et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials
Ananya Choudhury et al.
LANCET ONCOLOGY (2021)
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation
A. M. Brunt et al.
CLINICAL ONCOLOGY (2021)
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
Selvakumar Anbalagan et al.
SCIENTIFIC REPORTS (2021)
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
Sarah L. Kerns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer
Ivan R. Vogelius et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Prostate high dose -rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Adrian Murray Brunt et al.
LANCET (2020)
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer
Adrian Murray Brunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial
David Ball et al.
LANCET ONCOLOGY (2019)
Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation
Emely Kjellsson Lindblom et al.
MEDICAL PHYSICS (2019)
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Douglas H. Brand et al.
LANCET ONCOLOGY (2019)
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
Petra Seibold et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management
Kamran A. Ahmed et al.
EBIOMEDICINE (2019)
Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology
A. Wilkins et al.
CLINICAL ONCOLOGY (2018)
Big-RT: Big Data analysis to identify predictors of radiotherapy toxicity for personalised treatment
N. Somaiah et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C. Quon et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles N. Catton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
Charlotte E. Coles et al.
LANCET (2017)
Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
Yuta Shibamoto et al.
JOURNAL OF RADIATION RESEARCH (2016)
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
Shafak Aluwini et al.
LANCET ONCOLOGY (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial
A. Murray Brunt et al.
RADIOTHERAPY AND ONCOLOGY (2016)
Where Do We Look for Markers of Radiotherapy Fraction Size Sensitivity?
N. Somaiah et al.
CLINICAL ONCOLOGY (2015)
Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery
Chang W. Song et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
The Royal College of Radiologists' fractionation survey (Reprinted from Clinical Oncology vol 1, pg 39-46)
T. J. Priestman et al.
CLINICAL ONCOLOGY (2014)
Modelling the Impact of Fractionation on Late Urinary Toxicity After Postprostatectomy Radiation Therapy
Claudio Fiorino et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
On the Sensitivity of α/β Prediction to Dose Calculation Methodology in Prostate Brachytherapy
Hossein Afsharpour et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Alpha/Beta Ratio for Normal Lung Tissue as Estimated From Lung Cancer Patients Treated With Stereotactic Body and Conventionally Fractionated Radiation Therapy
Alize E. H. Scheenstra et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Dose Escalation, Not New Biology, Can Account for the Efficacy of Stereotactic Body Radiation Therapy With Non-Small Cell Lung Cancer
J. Martin Brown et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
Joanne S. Haviland et al.
LANCET ONCOLOGY (2013)
Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy
Navita Somaiah et al.
RADIOTHERAPY AND ONCOLOGY (2013)
The Relationship Between Homologous Recombination Repair and the Sensitivity of Human Epidermis to the Size of Daily Doses Over a 5-Week Course of Breast Radiotherapy
Navita Somaiah et al.
CLINICAL CANCER RESEARCH (2012)
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
Nicholas D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS)
Heon Joo Park et al.
RADIATION RESEARCH (2012)
ESTIMATION OF α/β FOR LATE RECTAL TOXICITY BASED ON RTOG 94-06
Susan L. Tucker et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
21 years of Biologically Effective Dose
J. F. Fowler
BRITISH JOURNAL OF RADIOLOGY (2010)
Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma
Peter J. Hoskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial
Jens Overgaard et al.
LANCET ONCOLOGY (2010)
Modeling of α/β for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer
Simona Marzi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial
J Yarnold et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients
C Ortholan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Loss of biological effect in prolonged fraction delivery
JF Fowler et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma - Clinical outcomes in 245 subjects in a Japanese multinstitutional study
H Onishi et al.
CANCER (2004)
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
J Overgaard et al.
LANCET (2003)
What hypofractionated protocols should be tested for prostate cancer?
JF Fowler et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
分享论文
